MIRM Q2 2024 Earnings — Mirum Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MIRMMirum Pharmaceuticals, Inc.

$5B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$78M+107.7% YoY

Gross Profit

$58M74.0% margin

Operating Income

-$24M-31.1% margin

Net Income

-$25M-31.6% margin

EPS (Diluted)

$-0.52

QoQ Revenue Growth

+12.5%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$15M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$661M

Total Liabilities

$432M

Stockholders' Equity

$229M

Cash & Equivalents

$233M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$78M	$37M	+107.7%
Gross Profit	$58M	$31M	+87.9%
Operating Income	-$24M	-$24M	+0.2%
Net Income	-$25M	-$74M	+66.7%

Revenue Segments

Product

$78M100%

License and Other Revenue

$115,0000%

Geographic Segments

UNITED STATES

$65M84%

Rest Of World

$13M16%